Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CORT 
Corcept Therapeutics Incorporated (CORT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CORT (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 11.91% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.05B USD | Price to earnings Ratio 92.86 | 1Y Target Price 139.5 |
Price to earnings Ratio 92.86 | 1Y Target Price 139.5 | ||
Volume (30-day avg) 1826459 | Beta 0.61 | 52 Weeks Range 20.84 - 117.33 | Updated Date 03/31/2025 |
52 Weeks Range 20.84 - 117.33 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.23 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 20.92% | Operating Margin (TTM) 13.89% |
Management Effectiveness
Return on Assets (TTM) 11.71% | Return on Equity (TTM) 23.81% |
Valuation
Trailing PE 92.86 | Forward PE 29.24 | Enterprise Value 5387254490 | Price to Sales(TTM) 17.85 |
Enterprise Value 5387254490 | Price to Sales(TTM) 17.85 | ||
Enterprise Value to Revenue 7.98 | Enterprise Value to EBITDA 38.96 | Shares Outstanding 105503000 | Shares Floating 86917947 |
Shares Outstanding 105503000 | Shares Floating 86917947 | ||
Percent Insiders 11.44 | Percent Institutions 81.8 |
Analyst Ratings
Rating 4.6 | Target Price 74.9 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Corcept Therapeutics Incorporated
Company Overview
History and Background
Corcept Therapeutics Incorporated was founded in 1998. It focuses on the development and commercialization of drugs to treat severe metabolic, oncologic, and psychiatric disorders by modulating the effects of cortisol.
Core Business Areas
- Drug Development and Commercialization: Focused on developing and commercializing medications for conditions impacted by cortisol dysregulation. The primary product is Korlym (mifepristone) for Cushing's syndrome.
Leadership and Structure
Corcept's leadership includes Joseph Belanoff, MD (CEO), and Sean Maduck (CFO). The company operates with a research and development, commercial, and administrative structure.
Top Products and Market Share
Key Offerings
- Exkivity (mobocertinib): Corcept acquired exkivity for oncology treatment, it is less significant to overall revenue.
- Korlym (mifepristone): Korlym is Corcept's primary product, approved for treating Cushing's syndrome. Corcept holds a significant market share in the Cushing's syndrome drug market. Competitors include generic mifepristone and surgical interventions. Revenue from Korlym constitutes the majority of Corcept's total revenue. As of 2023, Corcept controlled the vast majority of the pharmaceutical market for Cushing's syndrome treatment.
Market Dynamics
Industry Overview
The pharmaceutical industry focusing on endocrine disorders, particularly those related to cortisol regulation, is a niche market with potential for growth due to the unmet medical needs.
Positioning
Corcept is a leader in the development and commercialization of drugs modulating cortisol activity. Its competitive advantage lies in its expertise and intellectual property surrounding mifepristone and related compounds.
Total Addressable Market (TAM)
The TAM for Cushing's syndrome treatment is estimated to be in the hundreds of millions of dollars annually. Corcept, with its dominant market share, is well-positioned to capture a significant portion of this TAM. The potential TAM for broader cortisol-related indications is substantially larger, potentially reaching billions of dollars.
Upturn SWOT Analysis
Strengths
- Strong patent protection for Korlym
- Deep understanding of cortisol modulation
- Established commercial infrastructure
- High profit margins on Korlym sales
- Acquired novel cancer therapy to diversify
Weaknesses
- Reliance on a single primary product (Korlym)
- Risk of generic competition upon patent expiration
- Potential for off-label use of generic mifepristone
- High cost of drug development
Opportunities
- Expansion into new indications for cortisol modulators
- Development of next-generation cortisol antagonists
- Potential partnerships with other pharmaceutical companies
- Further geographic expansion
Threats
- Patent challenges from competitors
- Regulatory hurdles for new drug approvals
- Changes in reimbursement policies
- Emergence of novel therapies for Cushing's syndrome
- Pricing pressures from payers
Competitors and Market Share
Key Competitors
- TEVA
- PFE
- MRK
Competitive Landscape
Corcept's advantage lies in its focus on cortisol modulation and its established position in the Cushing's syndrome market. Competitors have broader portfolios but lack Corcept's specific expertise.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Corcept has experienced significant growth in recent years, primarily driven by increasing sales of Korlym.
Future Projections: Analysts project continued growth for Corcept, driven by further penetration of the Cushing's syndrome market and potential new indications for cortisol modulators. Expectations are for revenue to approach $1 Billion.
Recent Initiatives: Recent initiatives include expanding clinical trials to study new indications for Korlym and developing next-generation cortisol antagonists.
Summary
Corcept Therapeutics is a strong company with a dominant position in the Cushing's syndrome market. Its reliance on a single product represents a weakness, and patent protection is crucial. The company has strong growth potential in new applications but needs to diversify its product line. The acquisition of oncology assets might help address this risk.
Similar Companies
- TEVA
- PFE
- MRK
- SNY
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Corcept Therapeutics Incorporated
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2004-04-14 | Co-Founder, President, CEO & Director Dr. Joseph K. Belanoff M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 500 | Website https://www.corcept.com |
Full time employees 500 | Website https://www.corcept.com | ||
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.